Valeur202020212022202320242025TTMFrais de vente, généraux et administratifs———————Recherche et développement———————Résultat d'exploitation———————Total des produits hors exploitation———————Charges d'intérêts, nettes des intérêts capitalisés———————Résultat hors exploitation, hors charges d'intérêts———————Revenus/dépenses exceptionnels———————Résultat avant impôts———————Part des actionnaires dans le résultat———————Impôts———————Intérêts ne donnant pas le contrôle / intérêts minoritaires———————Autres produits/charges après impôts———————Résultat net avant activités abandonnées———————Activités abandonnées———————Résultat net———————Ajustement de dilution———————Dividendes privilégiés———————Résultat net dilué revenant aux actionnaires ordinaires———————Bénéfice par action de base (BPA de base)———————Bénéfice par action dilué (BPA dilué)———————Nombre moyen d'actions de base en circulation———————Nombre d'actions en circulation après dilution———————EBITDA———————EBIT———————Coût des ventes———————Autres coûts des ventes———————Amortissements (flux de trésorerie)———————
Fresenius Medical Care AG American Depositary Shares (Each repr
Fresenius Medical Care AG & Co. KGaA is a German healthcare company which provides kidney dialysis services through a network of 4,171 outpatient dialysis centers, serving 345,425 patients. The company primarily treats end-stage renal disease, which requires patients to undergo dialysis 3 times per week for the rest of their lives.
With a global headquarters in Bad Homburg vor der Höhe, Germany, and a North American headquarters in Waltham, Massachusetts, it has a 38% market share of the dialysis market in the United States. It also operates 42 production sites, the largest of which are in the U.S., Germany, and Japan.
The company is 32% owned by Fresenius and, as of 2020, generates around 50% of the group's revenue.
As of 2024, the company was ranked as #612 on the World's Best Employers list published by Forbes.